Best Life Sciences Companies in Occitanie, France
The 99 best Life Sciences companies in Occitanie, France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Sensorion.
Our analysis of 50 Life Sciences companies
$3.3b in tracked funding; 62% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Occitanie
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Sensorion Provider of gene therapies for the treatment and prevention of inner ear disorders to restore hearing in… 62Funding top 11%News top 18%Patents top 20%Innovation top 28% All 11 signals ▾Fundingtop 11% Newstop 18% Patentstop 20% Innovationtop 28% Growthtop 37% Moattop 41% Talenttop 49% Marketbottom 49% Globalbottom 43% Partnersbottom 35% Techbottom 33% Funding: Raised $205M across 4 rounds · 4 rounds over 3 yrs (1.3/yr) News: 10 BI events in 12 mo (of 52 tracked, 8 types) · +67% YoY rank vs industry peers · Fliar Intelligence Index 62/100 | $205M | 4 mo ago | 50 | Nawal Ouzren CEO & Director | WordPressMySQLPHP+14 | Top 5M | 119 patents Inner ear drug and gene therapies plus cochlear delivery devices for hearing preservation | — |
| 2 | Abionyx Developer of therapeutics for treating rare diseases and severe inflammatory conditions | $155M | 54 mo ago | 63 | Cyrille Tupin CEO | JoomlaPleskPHP+11 | Top 10M | — | — |
| 3 | MedinCell Developer of a portfolio of long-acting injectables in various therapeutic areas 76Patents top 13%Product top 14%Innovation top 18%Funding top 23% All 11 signals ▾Patentstop 13% Producttop 14% Innovationtop 18% Fundingtop 23% Growthtop 25% Newstop 31% Moattop 35% Techtop 42% Markettop 45% Globalbottom 43% Talentbottom 41% Patents: 303 patents matched (strict assignee match) · 179 filings since 2022 vs 81 in 2017-21 Product: 9 distinct product lines · Company stage: Public rank vs industry peers · Fliar Intelligence Index 76/100 | $104M | 16 mo ago | 143 | Christophe Douat CEO | WordPressApple iCloud MailMySQL+29 | Top 5M | 303 patents Advanced pharmaceutical formulations and targeted drug delivery systems for controlled release. | — |
| 4 | Quantum Surgical Provider of surgical robotics for minimally invasive surgeries | $98M | 26 mo ago | 98 | Fernand Badano Co-Founder | WordPressMySQLPHP+14 | Top 10M | 224 patents Image‑guided needle placement and robotic navigation for minimally invasive procedures | — |
| 5 | Antabio Early-stage drug discovery company developing compounds for multi-drug resistant bacterial infections | $42M | 30 mo ago | 14 | — | WordPressMySQLPHP+18 | Top 50M | — | 1 job opening · 1 launch |
| 6 | Kinvent Provider of a device for physical rehabilitation and sports biomechanics 42Product top 34%Funding top 35%Talent top 38%Growth top 45% All 8 signals ▾Producttop 34% Fundingtop 35% Talenttop 38% Growthtop 45% Techtop 45% Globalbottom 36% Marketbottom 34% Newsbottom 22% Product: 4 published apps (8.1k installs) · Company stage: Series B Funding: Raised $27.4M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $27M | 29 mo ago | — | Odys Odys Co-CEO | WordPressMySQLPHP+24 | Top 5M | — | — |
| 7 | SeqOne Provider of bioinformatics tools for the analysis of genome sequencing data 55Growth top 32%Moat top 37%Funding top 38%Patents top 44% All 10 signals ▾Growthtop 32% Moattop 37% Fundingtop 38% Patentstop 44% Innovationtop 47% Techtop 48% Markettop 50% Talentbottom 49% Globalbottom 36% Newsbottom 20% Growth: Web rank 10,000,000 → 5,000,000 YoY · 1 acquisition/expansion move in 24 mo Moat: Editorial + unicorn rating 6/10 · IP moat: 18 patents rank vs industry peers · Fliar Intelligence Index 55/100 | $26M | 12 mo ago | 70 | Nicolas Philippe CEO | WebflowApple iCloud MailGoogle Workspace+19 | Top 5M | 18 patents Bioinformatics platforms for genomic HRD detection, structural variant identification, and phenotyping support | 1 partnership |
| 8 | GamaMabs Developer of engineered monoclonal antibodies for the treatment of ovarian cancer | $22M | 126 mo ago | 7 | — | — | — | — | — |
| 9 | Microphyt Microalgae-based natural solutions for nutrition, well-being, and advanced beauty 53Patents top 20%Innovation top 27%Moat top 32%Funding top 37% All 10 signals ▾Patentstop 20% Innovationtop 27% Moattop 32% Fundingtop 37% Producttop 40% Growthtop 45% Techbottom 47% Marketbottom 42% Globalbottom 40% Newsbottom 27% Patents: 97 patents matched (strict assignee match) · 37 filings since 2022 vs 23 in 2017-21 Innovation: 97 patents (top 14% of patent-holders) · 37 filings since 2022 vs 23 in 2017-21 rank vs industry peers · Fliar Intelligence Index 53/100 | $18M | 42 mo ago | 59 | — | WordPressMySQLSalesforce+22 | Top 10M | 97 patents Microalgae-derived bioactive ingredients for cosmetics, nutraceuticals, and cognitive health | — |
| 10 | Advicenne Developing paediatrics drugs for CNS and nephrology (including orphan) disorders | $17M | 111 mo ago | 1 | Didier Laurens Chief Executive Officer | WordPressTypeScriptPHP+22 | Top 10M | 42 patents Extended-release oral dosage forms for sultiame and citrate‑based therapies for cystinuria | — |
| 11 | Flash Therapeutics Provider of gene-based therapeutics for multiple disorders | $12M | 59 mo ago | 49 | — | — | — | 37 patents Apelin-based lymphedema therapy and viral RNA/genome‑editing delivery platforms | — |
| 12 | Phost'In Anti-cancer small molecules for the treatment of aggressive solid tumors & glioblastoma | $11M | 73 mo ago | 15 | Norbert Bakalara Co-Founder | — | — | — | — |
| 13 | Indatech Offering mass spectroscopy for early-stage development | $9M | 65 mo ago | 15 | Chauchard Fabien Co-Founder | — | — | 22 patents Raman immersion probes for spectroscopic analysis of particle clusters and material inhomogeneities | 1 launch |
| 14 | Ixaltis Drugs for the treatment of stress urinary incontinence. | $9M | 120 mo ago | 2 | Roberto Gradnik CEO | — | — | 2 patents Pharmaceutical piperidine compounds for treating urinary incontinence | — |
| 15 | Dedienne Sante A range of orthopedic implants | $9M | 216 mo ago | 450 | — | WordPressMySQLPHP+21 | Top 10M | 55 patents Orthopedic implant anchoring devices and surgical tools for hip replacement procedures. | 1 expansion |
| 16 | BOYDSense Developer of a breath-based diabetes monitor | $8M | 26 mo ago | 9 | — | — | — | — | — |
| 17 | AcuSurgical Provider of robotic technologies for retinal micro-surgery | $7M | 64 mo ago | 17 | Christoph Spuhler CEO | — | — | 25 patents Ophthalmic surgical instruments and robotic control interfaces for eye procedures | — |
| 18 | NanoMedSyn Enzyme replacement therapies for the treatment of Lysosomal Storage Disorders | $7M | 120 mo ago | — | Jean Durand Co-Founder | — | — | 33 patents Targeted drug delivery via cation‑independent mannose‑6‑phosphate receptor for bone therapeutics | — |
| 19 | Intrasense Designs, develops a software suite for the advanced visualization and post-processing of multimodal medical… | $6M | 125 mo ago | 61 | — | WordPressMySQLSalesforce+28 | Top 10M | 23 patents Advanced lung image processing, ROI mapping, and interactive visualization for medical diagnostics | 1 launch |
| 20 | Biodol Therapeutics Developer of therapeutic solutions for treating chronic neuropathic pain | $5M | 69 mo ago | 8 | Fabien Granier Co-Founder & CEO | — | — | 23 patents FLT3 kinase inhibitor heteroaryl benzamide compounds for targeted cancer therapy | — |
| 21 | X-Pressure Provider of a medical device to measure cerebrospinal fluid pressure to diagnose brain diseases | $5M | 35 mo ago | 3 | Eric Schmidt Co-Founder | — | — | 2 patents Electro‑medical diagnostic and measurement devices for patient monitoring | 1 launch |
| 22 | Nosopharm Anti-infective drug discovery targeting the bacterial multidrug resistance to antibiotics | $4M | 100 mo ago | 7 | — | — | — | 36 patents Design and synthesis of peptide-based antibiotics and bioactive peptide therapeutics. | — |
| 23 | Neurinnov Developer of active implantable medical devices to restore the function of the hand | $3M | 54 mo ago | 10 | David Andreu Co-Founder | — | — | 31 patents Implantable closed-loop neural stimulation with interleaved pulses and distributed bus communication | — |
| 24 | REEV Developer of AI-powered exoskeletons and gait analysis tools for mobility recovery. 48Growth top 35%Talent top 38%Funding top 40%AI top 45% All 8 signals ▾Growthtop 35% Talenttop 38% Fundingtop 40% AItop 45% Producttop 46% Techbottom 47% Globalbottom 43% Marketbottom 26% Growth: Fresh capital in last 24 mo Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 48/100 | $3M | 16 mo ago | 16 | Robin Temporelli CTO & Co-Founder - Technical and operational manager for the development of electromedical products | WordPressMySQLPHP+29 | Top 10M | — | — |
| 25 | Kyanos Developer of microalgae-based supplements for multiple health ailments | $3M | 61 mo ago | 16 | Vinh Ly Founder & CEO | — | — | — | — |
| 26 | Surgimab Near-infrared fluorescent antibody conjugates as in vivo diagnostic agents for cancer | $2M | 74 mo ago | 4 | — | — | — | 28 patents Fluorescently labeled biomolecules for medical imaging and diagnostic assays | — |
| 27 | Ambiotis Provider of preclinical developmental services in inflammatory assays, mediators, and lipid analysis | $1M | 97 mo ago | 11 | Marc Dubourdeau Founder & CEO | JoomlaAwesompletePHP+9 | Top 50M | — | — |
| 28 | Acobiom Developer of diagnostics for personalized medicine applications and provided omics services | $1M | 64 mo ago | 7 | David Piquemal Co-Founder & CSO | WordPressMySQLPHP+24 | Top 10M | 26 patents Predictive biomarkers for pancreatic cancer survival prognosis | — |
| 29 | Physiogenex Preclinical CRO focusing on metabolic disorders | $1M | 189 mo ago | 21 | — | WordPressMySQLPHP+15 | Top 50M | — | 1 job opening |
| 30 | Telegrafik Provider of IoT based solution for elderly care | $1M | 79 mo ago | 17 | Carole Garat Founder & CEO | WordPressMySQLPHP+17 | Top 50M | — | — |
| 31 | Recfrance Developer of a wide range of orthopedic paramedical equipment | $1M | 149 mo ago | 18 | Richard Juszkiewicz Co-Founder & President | — | — | 12 patents Orthopedic patient positioning and mobility assistance devices, including connected lifting systems. | — |
| 32 | Univercell Biosolutions Platform for human endocrine cell line generation | $711K | 112 mo ago | 11 | Guillaume Costecalde Chairman & CEO | — | — | 7 patents Human pancreatic beta cell lines and primate cardiovascular progenitor cells for disease modeling and drug screening | — |
| 33 | Vaiomer Provider of microbiome-based biomarker identification services | $555K | 89 mo ago | 11 | Rémy Burcelin Co-founder & CSO | — | — | 28 patents Therapeutic polydextrose formulations and factor‑Xa‑based glycemic agents; microbiome‑driven hepatic fibrosis diagnostics | — |
| 34 | Dexstr Digital clinical data management tool for providers | $336K | 128 mo ago | 8 | — | — | — | — | — |
| 35 | NovaGray Developer of radiotherapy based cancer treatment | $118K | 92 mo ago | 4 | Clemence Franc Co-Founder & President | WordPressMySQLPHP+18 | Top 5M | 22 patents Patents concentrated in computing, sensing & instrumentation | — |
| 36 | ICELLTIS Provider of human cells for research purposes | $110K | 118 mo ago | — | Veronique Santran Owner | — | — | — | — |
Top 12 Life Sciences companies in Occitanie
#1
Public · Montpellier, Occitanie · founded 2009 · 50 employees$205.3Mraised▾
Provider of gene therapies for the treatment and prevention of inner ear disorders to restore hearing in patients. It offers deep research platform aimed at understanding the pathophysiology and causes of inner ear diseases to develop effective therapeutic solutions. It offers SENS-501 a gene therapy for severe hearing loss due to OTOF gene mutations, and GJB2-GT targeting hearing loss from mutations in the GJB2 gene.
- Jan 2026Post IPO$95.7M
- Apr 2024Post IPO$16.8M
- Feb 2024Post IPO$54.4M
- Aug 2023Post IPO$38.4M
#2
Public · Jacou, Occitanie · founded 2002 · 143 employees$104.5Mraised▾
Developer of a portfolio of long-acting injectables in various therapeutic areas. The products developed are a subcutaneous injection for Schizophrenia, MDC-CWM; an intra-articular injection for pain and inflammation, MDC-TJK; subcutaneous injection for Schizophrenia in the preclinical stage. Additionally, the company has formulated six more injectables for various diseases.
- Feb 2025Post IPO$44.1M
- May 2023Post IPO$27.5M
- Nov 2019Grant (prize money)$4.8M
- Mar 2018Conventional Debt$24.6M
#3
Series A · Montpellier, Occitanie · founded 2017 · 70 employees$26.1Mraised▾
Provider of bioinformatics tools for the analysis of genome sequencing data. The platform helps researchers to detect & identify the variants responsible for gene mutation. It helps to detect many types of variants such as SNPs, Indels, CNVs, and mid-sized deletions.
- May 2025Series A$22.7M
- Jan 2022Series A$22.7M
- Mar 2019Series A$3.4M
#4
Series C · Montpellier, Occitanie · founded 2010 · 98 employees$98Mraised▾
Provider of surgical robotics for minimally invasive surgeries. It offers Epione robotic platform that helps in percutaneous ablation therapy for the treatment of liver cancer. It also treat inoperable tumors in the abdomen and the lungs. It enables physicians to treat tumors that are inoperable or particularly difficult to reach, due to their size or their location at an early stage without surgical intervention.
- Mar 2024Venture Debt$32.5M
- Oct 2021Series C$48M
- Jan 2020Grant (prize money)$2.2M
- Jun 2018Series A$50M
#5
Series B · Toulouse, Occitanie · founded 2021 · 16 employees$3.2Mraised▾
{}
- Feb 2025Series B$9.2M
- Sep 2023Series A$3.2M
- Jan 2023Seed$20K
#6
Series B · Labege, Occitanie · founded 2009 · 14 employees$41.6Mraised▾
Antabio is a French early-stage drug discovery company developing compounds for multi-drug resistant bacterial infections. The 2 lead programs are Metallo Beta-Lactamases inhibitors against E. coli NDM-1 strains and Pseudomonas Biofilms inhibitors in chronic respiratory infections. In 2013 and 2015 received funding from Wellcome Trust for EUR 4.7M and EUR 4 M respectively. The first candidate is a novel, safe and efficacious inhibitor of bacterial MBLs. It will be co-administered with a carbapenem to treat hospitalized patients suffering from complicated Gram-negative infections. The second candidate is an inhaled drug which can be used as an adjunct to existing antibiotic therapy and which will reduce the frequency and severity of Pseudomonas exacerbations by targeting both the virulence and persistence of biofilm-adapted infections.
- Dec 2023Series B$26.9M
- Jan 2020Grant (prize money)$4.4M
- Jul 2018Series A$6.1M
- Oct 2017Series A$8.6M
#7
Series B · Montpellier, Occitanie · founded 2016$27.4Mraised▾
Provider of a device for physical rehabilitation and sports biomechanics. It produces measuring and training devices for physiotherapy and fitness, including the K-Move joint mobility assessment tool and K-Force Plates for measuring balance. It also offer the Kinvent Physio app for physiotherapists and athletic trainers.
- Jan 2024Series B$19.6M
- 2022Series A$7.5M
- Nov 2018Seed$337.7K
#8
Public · Balma, Occitanie · founded 2005 · 63 employees$154.5Mraised▾
Developer of therapeutics for treating rare diseases and severe inflammatory conditions. The pipeline includes CER‑001 a recombinant apoA‑I HDL-mimetic under investigation for cardiovascular, rare genetic LCAT deficiency, severe inflammatory states, and even targeted delivery in oncology, CER-002 a peroxisome proliferator-activated receptor (PPAR) delta specific agonist in development for the treatment of cardiovascular diseases, and CER-209 is a oral P2Y13 receptor agonists for the treatment of atherosclerois and of non-alcoholic steato-hepatitis.
- Dec 2021Post IPO$4.8M
- Mar 2015Series C$4.1M
- Oct 2010Series C$13.9M
- Jul 2010Grant (prize money)$13.8M
#9
Series A · Toulouse, Occitanie · founded 2015 · 9 employees$7.6Mraised▾
Developer of a breath-based diabetes monitor. The Lassie breath analyzer is a non-invasive device for measuring critical biomarkers from exhaled breath and detects glucose levels. This device also detects and monitors other diseases such as cancer, obesity, asthma, and more.
- Apr 2024Series A$7.5M
- Grant (prize money)$61.3K
#10
Series B · Baillargues, Occitanie · founded 2007 · 59 employees$18.1Mraised▾
Microalgae-based natural solutions for nutrition, well-being, and advanced beauty. The company develops and markets microalgae-based solutions for health and beauty, creating a new generation of eco-efficient natural bioactives. They unlock the full potential of microalgae diversity using patented technology, offering innovative solutions and tailor-made innovation. Their focus is on novel nutrition and advanced beauty, with a commitment to better living and a blue future. They develop the next generation of natural ingredients for better living, with a focus on high CO2 capture, no pesticides used, and non-GMO practices. They offer ingredients designed to support overall gut-brain axis and holistic relaxation experiences. They are driven by innovation and committed to making a positive difference, fostering a blue future through sustainable practices.
- Nov 2022Series B$15.6M
- Jul 2019Grant (prize money)$2M
- Mar 2017Grant (prize money)$19K
- Aug 2016Grant (prize money)$2M
#11
Series A · Toulouse, Occitanie · founded 2021 · 3 employees$4.9Mraised▾
Provider of a medical device to measure cerebrospinal fluid pressure to diagnose brain diseases. It offers a sensor to the end of the lumbar puncture needle which meassure opening pressure using mobile application and AI-based algorithms.
- Jul 2023Series A$4.9M
#12
Series A · Toulouse, Occitanie · founded 2005 · 49 employees$11.5Mraised▾
Provider of gene-based therapeutics for multiple disorders. The company is developing gene and cell-based therapies for IPEX syndrome and lymphedema. The company has a lentiviral platform, transient RNA delivery, CAR-T cancer immunotherapy, and other gene-editing technology.
- Jul 2021Series A$4.7M
- May 2018Series A$3.9M
- Aug 2017Grant (prize money)$59.7K
- 2017Series A—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.